{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:54:28Z","timestamp":1790610868539,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40123-023-00647-7","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T15:05:20Z","timestamp":1673535920000},"page":"639-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Pierre","family":"Copt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Pr\u00fcnte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Seelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor M.","family":"Somfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"2","key":"647_CR1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144\u201360.","journal-title":"Lancet Glob Health"},{"key":"647_CR2","unstructured":"World Health Organization. Blindness and vision impairment. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment. Accessed 18 Nov 2022."},{"issue":"7","key":"647_CR3","first-page":"450","volume":"38","author":"KM Gehrs","year":"2000","unstructured":"Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration\u2013emerging pathogenetic and therapeutic concepts. Am Med. 2000;38(7):450\u201371.","journal-title":"Am Med"},{"issue":"8","key":"647_CR4","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1007\/s12325-022-02193-3","volume":"39","author":"RP Finger","year":"2022","unstructured":"Finger RP, Dennis N, Freitas R, et al. Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(8):3425\u201348.","journal-title":"Adv Ther"},{"issue":"3","key":"647_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3928\/23258160-20210302-02","volume":"52","author":"MR Starr","year":"2021","unstructured":"Starr MR, Xu D, Boucher N, et al. Characterizing progression to neovascular AMD in fellow eyes of patients treated with intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging Retina. 2021;52(3):123\u20138.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"647_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"647_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222.","journal-title":"Ophthalmologica"},{"issue":"11","key":"647_CR8","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham Y, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045, systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391.","journal-title":"Ophthalmology"},{"issue":"2","key":"647_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","volume":"181","author":"LA Kim","year":"2012","unstructured":"Kim LA, D\u2019Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Clin Pathol. 2012;181(2):376\u20139.","journal-title":"Am J Clin Pathol"},{"key":"647_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12886-022-02482-z","volume":"22","author":"J Wirkkala","year":"2022","unstructured":"Wirkkala J, Kubin AM, Ohtonen P, Yisela J, Siik T, Hautala N. Visual outcomes of observation, macular laser and anti-VEGF in diabetic macular edema in type 1 diabetes: a real-world study. BMC Ophthalmol. 2022;22:258.","journal-title":"BMC Ophthalmol"},{"key":"647_CR11","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1007\/s00417-021-05187-z","volume":"259","author":"J Zirpel","year":"2021","unstructured":"Zirpel J, Pfister IB, Gerhardt C, Garweg JG. Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. Graefes Arch Clin Exp Ophthalmol. 2021;259:3569\u201378.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"647_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14746","volume":"39","author":"T Peto","year":"2022","unstructured":"Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study. Diabet Med. 2022;39: e14746.","journal-title":"Diabet Med"},{"key":"647_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub6","author":"G Virgili","year":"2018","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018. https:\/\/doi.org\/10.1002\/14651858.CD007419.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"647_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","volume":"33","author":"RP Gale","year":"2019","unstructured":"Gale RP, Mahmood S, Devonport H. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33(Suppl 1):1\u201321.","journal-title":"Eye"},{"key":"647_CR15","doi-asserted-by":"publisher","first-page":"20256","DOI":"10.1038\/s41598-020-76354-1","volume":"10","author":"A Ebneter","year":"2020","unstructured":"Ebneter A, Michels S, Pruente C, et al. Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. Sci Rep. 2020;10:20256.","journal-title":"Sci Rep"},{"key":"647_CR16","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00417-020-05048-1","volume":"259","author":"JG Garweg","year":"2021","unstructured":"Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD)\u2014a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259:2181\u201392.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"647_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Skelly A, Bezlyak V, et al. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2020;4(2):122\u201333.","journal-title":"Ophthalmol Retina"},{"key":"647_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000514721","volume":"64","author":"H Giannakaki-Zimmermann","year":"2021","unstructured":"Giannakaki-Zimmermann H, Behrndt A, Hoffman L, et al. Predictors for 2-year functional and morphological outcomes of a treat-and-extend regimen with ranibizumab in patients with diabetic macular edema. Ophthalmic Res. 2021;64:465\u201375.","journal-title":"Ophthalmic Res"},{"issue":"4","key":"647_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Liu ZW, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725\u201331.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"647_CR20","doi-asserted-by":"publisher","first-page":"S552","DOI":"10.1016\/j.jval.2022.04.1406","volume":"25","author":"M Adams","year":"2022","unstructured":"Adams M, Holekamp N, Jackson T, et al. PCR61 Burden and impacts associated with caring for neovascular age-related macular degeneration and diabetic macular edema patients: a multinational caregiver survey. Value Health. 2022;25(7):S552.","journal-title":"Value Health"},{"key":"647_CR21","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12:2483\u201391.","journal-title":"Clin Ophthalmol"},{"key":"647_CR22","unstructured":"NHS England and NHS Improvement. Transforming NHS Outpatient Care. 2020. https:\/\/www.locsu.co.uk\/wp-content\/uploads\/2020\/11\/NHSEI-NOC-2020-25112020.pdf. Accessed 18 Nov 2022."},{"key":"647_CR23","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2147\/OPTH.S114006","volume":"10","author":"S Kiss","year":"2016","unstructured":"Kiss S, Chandwani HS, Cole AL, Patel VD, Lunacsek OE, Dugel PU. Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clin Ophthalmol. 2016;10:2443\u201353.","journal-title":"Clin Ophthalmol"},{"key":"647_CR24","doi-asserted-by":"publisher","first-page":"A399","DOI":"10.1016\/j.jval.2017.08.2391","volume":"20","author":"A Skelly","year":"2017","unstructured":"Skelly A, Ferreira A, Bezlyak V, Jaffe D. PSS13 The economic and humanistic burden of patients on treatment for neovascular age-related macular degeneration. Value Health. 2017;20:A399\u2013811.","journal-title":"Value Health"},{"key":"647_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3928\/23258160-20180221-06","volume":"49","author":"ME Jansen","year":"2018","unstructured":"Jansen ME, Krambeer CJ, Kermany DS, et al. Appointment compliance in patients with diabetic macular edema and exudative macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2018;49:186\u201390.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"647_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"647_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/aos.14183","volume":"98","author":"T Brynskov","year":"2020","unstructured":"Brynskov T, Munch IC, Larsen TM, Erngaard L, Sorensen TL. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol. 2020;98:132\u20138.","journal-title":"Acta Ophthalmol"},{"key":"647_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41433-020-0764-9","volume":"34","author":"S Chandra","year":"2020","unstructured":"Chandra S, Arpa C, Menon D, et al. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye. 2020;34:1888\u201396.","journal-title":"Eye"},{"key":"647_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ophtha.2018.11.036","volume":"126","author":"CL Nguyen","year":"2019","unstructured":"Nguyen CL, Gillies MC, Nguyen V, et al. Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. Ophthalmology. 2019;126:735\u201342.","journal-title":"Ophthalmology"},{"key":"647_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00425-w","author":"FJ Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez FJ, Wu L, Bordon AF, et al. Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study. Int J Retin Vitr. 2022. https:\/\/doi.org\/10.1186\/s40942-022-00425-w.","journal-title":"Int J Retin Vitr"},{"key":"647_CR31","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1111\/aos.14946","volume":"100","author":"R Angermann","year":"2022","unstructured":"Angermann R, Hofer M, Huber AL, et al. The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study. Acta Ophthalmol. 2022;100:e546\u201352.","journal-title":"Acta Ophthalmol"},{"key":"647_CR32","unstructured":"Swiss Public Assessment Report \u2013 Beovu. 2020. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/de\/dokumente\/zulassung\/swisspar\/67244-beovu-01-swisspar-20200306.pdf.download.pdf\/SwissPAR%20%E2%80%93%20Beovu.pdf. Accessed 18 Nov 2022."},{"key":"647_CR33","unstructured":"Swiss Public Assessment Report, extension of therapeutic indication \u2013 Beovu. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/fr\/dokumente\/zulassung\/swisspar\/67244-beovu-02-swisspar-20220803.pdf.download.pdf\/SwissPAR_final.pdf. Accessed 18 Nov 2022."},{"issue":"1","key":"647_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89\u201399.","journal-title":"Ophthalmology"},{"issue":"1","key":"647_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"key":"647_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajo.2021.10.017","volume":"236","author":"C Jhaveri","year":"2022","unstructured":"Jhaveri C, Wykoff CC, Khanani AM, et al. Early residual fluid-free status and long-term BCVA outcomes: a treatment agnostic, post hoc analysis of pooled HAWK and HARRIER data. Am J Ophthalmol. 2022;236:12\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"647_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.oret.2021.12.014","volume":"6","author":"RP Singh","year":"2022","unstructured":"Singh RP, Jhaveri C, Wykoff C, et al. Efficacy outcomes of brolucizumab versus aflibercept in neovascular age-related macular degeneration patients with early residual fluid. Ophthalmol Retina. 2022;6(5):377\u201386.","journal-title":"Ophthalmol Retina"},{"key":"647_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02077-4","author":"U Schmidt-Erfurth","year":"2022","unstructured":"Schmidt-Erfurth U, Mulyukov Z, Gerendas BS, et al. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye. 2022. https:\/\/doi.org\/10.1038\/s41433-022-02077-4.","journal-title":"Eye"},{"key":"647_CR39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050\u20139.","journal-title":"Ophthalmology"},{"key":"647_CR40","unstructured":"Regillo C, Kertes P, Kaiser PK, et al. TALON, a phase\u00a0IIIb study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 32-week primary outcomes. Presented at American Society of Retina Specialists, New York, July 13\u201316, 2022."},{"issue":"8","key":"647_CR41","first-page":"2561","volume":"260","author":"A Boltz","year":"2022","unstructured":"Boltz A, Radunksy K, Weingessel B, V\u00e9csei-Marlovits VP. Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2561\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"647_CR42","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/bjophthalmol-2020-318672","volume":"106","author":"LM Bulirsch","year":"2022","unstructured":"Bulirsch LM, Sassmannshausen S, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2022;106:1288\u201394.","journal-title":"Br J Ophthalmol"},{"key":"647_CR43","doi-asserted-by":"publisher","first-page":"28852894","DOI":"10.2147\/OPTH.S376199","volume":"16","author":"M Giunta","year":"2022","unstructured":"Giunta M, Meunier LG, Nixon D, Steeves J, Noble J. Early Canadian real-world experience with brolucizumab in anti-vascular endothelial growth factor-experienced patients with neovascular age-related macular degeneration: a retrospective chart review. Clin Ophthalmol. 2022;16:28852894.","journal-title":"Clin Ophthalmol"},{"key":"647_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","volume":"140","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration. JAMA Ophthalmol. 2022;140:20\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"647_CR45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","volume":"129","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Brown DM, Jaffe GJ, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2022;129:974\u201385.","journal-title":"Ophthalmology"},{"key":"647_CR46","unstructured":"Novartis. Novartis reports one year results of phase\u00a0III MERLIN study evaluating Beovu\u00ae every four week dosing and provides update on Beovu clinical program. 2021. https:\/\/www.novartis.com\/news\/media-releases\/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program. Accessed 18 Nov 2022."},{"key":"647_CR47","unstructured":"Swiss Medic Info. Beovu (Brolucizumab) product information. 2022. https:\/\/www.swissmedicinfo.ch\/Default.aspx. Accessed 18 Nov 2022."},{"key":"647_CR48","unstructured":"Schmouder RL, Maciejewski B, Karle A, et al. Immunologic features of Beovu\u00ae-associated retinal vasculitis\/retinal vascular occlusion. EURETINA 2021 Virtual Congress; September 9\u201312, 2021."},{"issue":"13","key":"647_CR49","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.3390\/jcm10132758","volume":"10","author":"A Bilgic","year":"2021","unstructured":"Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med. 2021;10(13):2758.","journal-title":"J Clin Med"},{"key":"647_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12886-022-02305-1","volume":"22","author":"I Barchichat","year":"2022","unstructured":"Barchichat I, Thiel M, Job O, Schmid M. Bilateral blindness after uneventful brolucizumab injection for macular degeneration. BMC Ophthalmol. 2022;22:80.","journal-title":"BMC Ophthalmol"},{"key":"647_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Bandello AE, Bandello F, et al. KESTREL and KITE: 52-week results from two phase\u00a0III pivotal trials of brolucizumab for diabetic macular edema 2022. Am J Ophthalmol. 2022;238:157\u201372.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"647_CR52","first-page":"3849","volume":"63","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Garweg JG, Regillo C, et al. Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies. Invest Ophthalmol Vis Sci. 2022;63(7):3849.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"647_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101197","volume":"24","author":"D Chakraborty","year":"2021","unstructured":"Chakraborty D, Sheth JU, Boral S, Sinha TK. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series. Am J Ophthalmol Case Rep. 2021;24: 101197.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"647_CR54","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41433-022-02008-3","volume":"36","author":"I Pearce","year":"2022","unstructured":"Pearce I, Amoaku W, Bailey C, et al. The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice. Eye. 2022;36:1725\u201334.","journal-title":"Eye"},{"key":"647_CR55","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","volume":"42","author":"FG Holz","year":"2022","unstructured":"Holz FG, Iida T, Maruko I, Sadda SR. A consensus on risk mitigation for brolucizumab in neovascular age-related macular degeneration - patient selection, evaluation, and treatment. Retina. 2022;42:1629\u201337.","journal-title":"Retina"},{"key":"647_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftale.2022.05.006","author":"A Fonollosa","year":"2022","unstructured":"Fonollosa A, Gallego-Pinazo R, Sararols L, Adan A, Lopez-Galvez M, Figueroa MS. Guidance on brolucizumab management recommendations. Arch Soc Esp Oftalmol. 2022. https:\/\/doi.org\/10.1016\/j.oftale.2022.05.006.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"647_CR57","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","volume":"5","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, et al. Brolucizumab\u2014early real-world experience: BREW study. Eye. 2021;5:1045\u20137.","journal-title":"Eye"},{"issue":"8","key":"647_CR58","first-page":"451","volume":"62","author":"AA Aziz","year":"2021","unstructured":"Aziz AA, Khanani AM, London N, et al. Real world efficacy and safety of brolucizumab in neovascular AMD: The REBEL study. Invest Ophthalmol Vis Sci. 2021;62(8):451.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"647_CR59","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/jcm10122666","volume":"10","author":"C Haensli","year":"2021","unstructured":"Haensli C, Pfister IB, Garweg JG. Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6-month outcomes. J Clin Med. 2021;10:2666.","journal-title":"J Clin Med"},{"key":"647_CR60","unstructured":"Khanani A, Sadda SR, Sarraf D, et al. Comparative assessment of the maximum thickness of pigment epithelial detachments and sub-RPE fluid in patients treated with brolucizumab versus aflibercept in the HAWK & HARRIER studies. Presented at EURETINA Virtual Meeting, September 2021."},{"key":"647_CR61","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","volume":"259","author":"I Maruko","year":"2021","unstructured":"Maruko I, Okada AA, Iida T, et al. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2021;259:2857\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"647_CR62","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Arch Clin Exp Ophthalmol. 2017;255:1259\u201373.","journal-title":"Arch Clin Exp Ophthalmol"},{"key":"647_CR63","unstructured":"National Institute for Health and Care Excellence (NICE). NICE guideline 82. Age-related macular degeneration. 2018. https:\/\/www.nice.org.uk\/guidance\/ng82. Accessed 18 Nov 2022."},{"issue":"3","key":"647_CR64","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00347-021-01321-8","volume":"118","author":"FG Holz","year":"2021","unstructured":"Holz FG, Heinz C, Wolf A, Hoerauf H, Pleyer U. Intraocular inflammation when using brolucizumab. Ophthalmologist. 2021;118(3):248\u201356.","journal-title":"Ophthalmologist"},{"key":"647_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1976220","author":"JG Garweg","year":"2021","unstructured":"Garweg JG, H\u00e4nsli C. Pitfalls in the interpretation of intraocular inflammation in response to intravitreal brolucizumab injection. Ocul Immunol Inflamm. 2021. https:\/\/doi.org\/10.1080\/09273948.2021.1976220.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"647_CR66","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2249.2009.03885.x","volume":"156","author":"CJW Tervaert","year":"2009","unstructured":"Tervaert CJW. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol. 2009;156(3):377\u201385.","journal-title":"Clin Exp Immunol"},{"key":"647_CR67","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s00431-022-04458-z","volume":"181","author":"L Scherler","year":"2022","unstructured":"Scherler L, Haas NA, Tengler A, Pattathu J, Mandilaras G, Jakob A. Acute phase of Kawasaki disease: a review of national guideline recommendations. Eur J Ped. 2022;181:2563\u201373.","journal-title":"Eur J Ped"},{"key":"647_CR68","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"J Li","year":"2022","unstructured":"Li J, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18:540\u201357.","journal-title":"Nat Rev Endocrinol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00647-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-023-00647-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00647-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T06:19:37Z","timestamp":1678688377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-023-00647-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["647"],"URL":"https:\/\/doi.org\/10.1007\/s40123-023-00647-7","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}